Compare · AXSM vs NMRA
AXSM vs NMRA
Side-by-side comparison of Axsome Therapeutics Inc. (AXSM) and Neumora Therapeutics Inc. (NMRA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. AXSM focuses on Biotechnology: Pharmaceutical Preparations, while NMRA focuses on Biotechnology: Biological Products (No Diagnostic Substances).
- AXSM is the larger of the two at $7.15B, about 115.5x NMRA ($61.9M).
- NMRA has been more active in the news (5 items in the past 4 weeks vs 4 for AXSM).
- AXSM has more recent analyst coverage (25 ratings vs 23 for NMRA).
- Company
- Axsome Therapeutics Inc.
- Neumora Therapeutics Inc.
- Price
- -
- -
- Market cap
- $7.15B
- $61.9M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- 2023
- News (4w)
- 4
- 5
- Recent ratings
- 25
- 23
Axsome Therapeutics Inc.
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05 for the treatment major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial for the treatment of Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. The company is also developing AXS-07 for the treatment of migraine; AXS-12 for the treatment of narcolepsy; and AXS-14 for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
Latest AXSM
- Axsome Therapeutics to Participate in Upcoming Investor Conferences
- SEC Form 10-Q filed by Axsome Therapeutics Inc.
- Axsome Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
- Axsome Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
- Axsome Therapeutics to Report Third Quarter 2026 Financial Results on November 2
- Truist resumed coverage on Axsome Therapeutics with a new price target
- Axsome Therapeutics Announces Results of the Shared Goals Survey of Caregivers of Patients with Alzheimer’s Disease Agitation Presented at Psych Congress 2026 in Connection with World Alzheimer’s Day
- Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026
- Chief Operating Officer Jacobson Mark L. sold $2,086,500 worth of shares (10,000 units at $208.65) as part of a pre-agreed trading plan and exercised 10,000 shares at a strike of $12.95 (SEC Form 4)
- Axsome Therapeutics to Participate in Upcoming Investor Conferences
Latest NMRA
- Amendment: SEC Form SCHEDULE 13G/A filed by Neumora Therapeutics Inc.
- SEC Form 10-Q filed by Neumora Therapeutics Inc.
- Neumora Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Neumora Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
- Neumora Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- Officer Aurora Daljit Singh exercised 176,060 shares at a strike of $0.72 and sold $269,967 worth of shares (176,060 units at $1.53) (SEC Form 4)
- SEC Form 4 filed by Officer Berns Paul L
- SEC Form 4 filed by Officer Duncan Jason
- SEC Form 4 filed by Officer Milligan Michael Lee
- SEC Form 4 filed by President & CEO Pinto Joshua